Cantor Fitzgerald Predicts PVLA FY2026 Earnings

Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share estimates for Palvella Therapeutics in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.73) per share for the year. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share.

Other equities analysts have also issued research reports about the company. Jones Trading assumed coverage on Palvella Therapeutics in a research note on Tuesday, March 25th. They issued a "buy" rating and a $45.00 price target on the stock. Canaccord Genuity Group cut their price target on Palvella Therapeutics from $53.00 to $52.00 and set a "buy" rating on the stock in a report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, April 30th. Chardan Capital started coverage on Palvella Therapeutics in a report on Wednesday, April 9th. They issued a "buy" rating and a $50.00 price objective on the stock. Finally, Scotiabank assumed coverage on Palvella Therapeutics in a report on Friday, March 7th. They issued a "sector outperform" rating and a $50.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $46.29.

Palvella Therapeutics Trading Down 5.2%

NASDAQ:PVLA traded down $1.37 during trading hours on Wednesday, hitting $25.05. The company had a trading volume of 223,837 shares, compared to its average volume of 70,759. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27. The business's 50-day moving average price is $23.76. The firm has a market capitalization of $276.95 million, a P/E ratio of -2.07 and a beta of -0.10.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.40) by $2.66.

Insider Buying and Selling

In related news, Director George M. Jenkins bought 2,500 shares of the stock in a transaction on Wednesday, April 9th. The shares were bought at an average cost of $20.13 per share, for a total transaction of $50,325.00. Following the purchase, the director now owns 183,171 shares of the company's stock, valued at $3,687,232.23. This trade represents a 1.38% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. 20.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Woodline Partners LP purchased a new position in shares of Palvella Therapeutics in the 1st quarter valued at approximately $5,435,000. Goldman Sachs Group Inc. acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at approximately $533,000. Millennium Management LLC acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at approximately $7,553,000. AWM Investment Company Inc. acquired a new stake in shares of Palvella Therapeutics in the 1st quarter valued at approximately $1,943,000. Finally, Frazier Life Sciences Management L.P. lifted its holdings in shares of Palvella Therapeutics by 5.5% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 690,012 shares of the company's stock valued at $19,313,000 after buying an additional 36,120 shares during the period. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.